Long-Term Safety and Efficacy of a Once-Daily Formulation of Alfuzosin 10 mg in Patients with Symptomatic Benign Prostatic Hyperplasia: Open-Label Extension Study

By van Kerrebroeck P.   Jardin A.   van Cangh P.   Laval K.U.   The ALFORTI Study Group  

European Urology, Vol. 41, Iss. 1, 2002-01 ,pp. : 54-61

Elsevier

Access to resources Recommend Favorite

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia

By Elhilali M.M.   Ramsey E.W.   Barkin J.   Casey R.W.   Boake R.C.   Beland G.   Fradet Y.   Trachtenberg J.   Orovan W.L.   Schick E.   Klotz L.H.  

Urology, Vol. 47, Iss. 3, 1996-03 ,pp. : 335-342

Elsevier

Access to resources Recommend Favorite

Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia

By Lowe F.C.   McConnell J.D.   Hudson P.B.   Romas N.A.   Boake R.   Lieber M.   Elhilali M.   Geller J.   Imperto-McGinely J.   Andriole G.L.   Bruskewitz R.C.   Walsh P.C.   Bartsch G.   Nacey J.N.   Shah S.   Pappas F.   Ko A.   Cook T.   Stoner E.   Waldstreicher J.   FINASTERIDE STUDY GROUP  

Urology, Vol. 61, Iss. 4, 2003-04 ,pp. : 791-796

Elsevier

Access to resources Recommend Favorite

Long-term outcome of prostatic stent treatment for benign prostatic hyperplasia

By Chiou R.K.   Chen W.S.   Akbari A.   Foley S.   Lynch B.   Taylor R.J.  

Urology, Vol. 48, Iss. 4, 1996-10 ,pp. : 589-593

Elsevier

Access to resources Recommend Favorite

Short-term efficacy and long-term compliance/treatment failure of the α1 blocker naftopidil for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia

By Masumori Naoya   Hashimoto Jiro   Itoh Naoki   Tsukamoto Taiji   Group The Sapporo Medical University Naftopidil Study  

Scandinavian Journal of Urology and Nephrology, Vol. 41, Iss. 5, 2007-01 ,pp. : 422-429

Informa Healthcare

Access to resources Recommend Favorite